<DOC>
	<DOCNO>NCT00556673</DOCNO>
	<brief_summary>This study design evaluate bronchodilatory efficacy indacaterol maleate 500 μg/mometasone furoate 400 μg via Twisthaler® device adult patient persistent asthma .</brief_summary>
	<brief_title>Bronchodilatory Efficacy Single Dose QMF149 ( Indacaterol Maleate/Mometasone Furoate ) Via Twisthaler® Device Adult Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Male female adult patient age 1875 year persistent asthma Patients persistent asthma , diagnose accord Global Initiative Asthma guideline ( GINA ) additionally meet follow criterion : 1 . Patients receive daily treatment inhale corticosteroid maximum dose per day indicate package leaflet , stable regimen month prior Visit 1 . 2 . Patients force expiratory volume 1 second ( FEV1 ) Visit 1 ≥ 50 % predict normal value . This criterion FEV1 demonstrate washout period least 6 hour short act β2agonist inhale , minimum 48 hour long act β2agonist . 3 . Patients demonstrate increase ≥12 % ≥200 mL FEV1 prebronchodilator value 30 minute inhale total 200 μg salbutamol ( albuterol ) via meter dose inhaler ( MDI ) ( reversibility test ) . Reversibility demonstrate appropriate washout period least 6 hrs prior evaluation shortacting β2agonist . The administration salbutamol ( albuterol ) reversibility test within 30 minute prebronchodilator spirometry . Reversibility demonstrate Visit 1 Visits 1 2 , order patient include trial . 4 . For patient , small value Visit 1 FEV1 Visit 2 FEV1 predose value least 85 % large value . Body mass index ( BMI ) 18 32 kg/m^2 weight &gt; 50 kg . patient use local contraception Pregnant nursing woman Recent use tobacco history smoking &gt; 10 pack year Patients diagnose chronic obstructive pulmonary disease ( COPD ) Patients recent experience severe asthma attack/exacerbation within 6months study start Patients frequent rescue medication ( &gt; 8 puffs/day two consecutive day ) Clinically relevant laboratory abnormality clinically significant condition Active cancer history cancer le 5 year disease free survival time History long QT syndrome long QTc interval prior dose History hypersensitivity study drug drug similar chemical structure Use certain medication Use investigational drug A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result History immunodeficiency disease , include positive human immumodeficiency virus ( HIV ) test result . History drug alcohol abuse evidence abuse Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Asthma , QMF149 , fix combination indacaterol mometasone furoate</keyword>
</DOC>